Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
1,023
Views
16
CrossRef citations to date
0
Altmetric
Reviews

Modeling the chronic lymphocytic leukemia microenvironment in vitro

Kyle Crassinia Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia
,
Yandong Shena Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia
,
Stephen Mulligana Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia;b Chronic Lymphocytic Leukemia Research Consortium (CLLARC), Australia
&
O. Giles Besta Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia;b Chronic Lymphocytic Leukemia Research Consortium (CLLARC), AustraliaCorrespondence[email protected]
Pages 266-279 | Received 14 Mar 2016, Accepted 15 Jun 2016, Published online: 18 Oct 2016
Supplemental material

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Download Zip (4.4 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Source: Springer Science and Business Media LLC
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Source: Wiley

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.